Validating AI-Powered Prognostic Model for Early-Stage Breast Cancer Patients

Birmingham, AL - Researchers are working to validate a cutting-edge artificial intelligence (AI) model designed to predict long-term clinical outcomes in patients with early-stage hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer. The study aims to integrate digital pathology images with limited clinical data to provide more accessible and cost-effective biomarker testing than traditional molecular assays.

According to the American Cancer Society, approximately one-third of all newly diagnosed cancers in women each year are breast cancer cases. With a median age at diagnosis of 62 years, this type of cancer is relatively rare among younger women. Despite some fluctuations over the past few years, incidence rates have been rising by about 1% annually.

The study’s focus on early-stage invasive breast cancer patients with HR+/HER2− subtype highlights the need for more effective prognostic and predictive tools in cancer care. Enhancing these tools has the potential to improve patient quality of life while reducing overall disease burden. Artera’s multimodal AI (MMAI) model is designed to support clinicians in making risk-based decisions for adult women with HR-positive early-stage breast cancer who have no clinically or pathologically defined distant metastases, within recommended clinical guidelines.

The study will use a retrospective chart-review approach, analyzing patients with a median follow-up of 10 years. Participants with noninvasive disease (pTis) or recurrent or metastatic disease (pM1) at baseline were excluded from the analysis. The primary end point is distant recurrence or metastasis, while exploratory end points include breast cancer–specific mortality, overall survival, and recurrence- or disease-free survival.

The study’s data analysis tools will leverage digital pathology images with limited clinical data to generate a prognostic algorithm score of interest. This unique approach addresses critical gaps in cancer care by providing more accessible, rapid, and cost-effective biomarker testing than traditional molecular assays. By validating Artera’s MMAI model, researchers hope to improve patient outcomes and streamline the decision-making process for clinicians.

Enrollment at the University of Alabama at Birmingham (UAB) Hospital is anticipated to be completed by April 2026.